Amylin Completes BLA Submission
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) recently completed the submission of its rolling Biologics License Application (BLA) for metreleptin to the US Food and Drug Administration (FDA). Amylin is looking to get metreleptin approved for the treatment of diabetes and/or high levels of triglycerides in the bloodstream (hypertriglyceridemia) in pediatric and adult patients suffering from rare forms [...]
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) recently completed the submission of its rolling Biologics License Application (BLA) for metreleptin to the US Food and Drug Administration (FDA).
Amylin is looking to get metreleptin approved for the treatment of diabetes and/or high levels of triglycerides in the bloodstream (hypertriglyceridemia) in pediatric and adult patients suffering from rare forms of lipodystrophy.
Amylin had initiated the filing of the rolling BLA for metreleptin in December 2010. … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards